Short Title:
MERA Maturation
Responsible HRP Element:
Space Radiation
Funding Status:
Planned-Unfunded - Task not within current budget
|
Procurement Mechanism(s):
|
|
Aims:
Ongoing use of ensemble modeling approach for risk assessment where REID acceptance is determined based on the region of overlap between multiple predictive models to integrate:
1. Common risk quantification parameters across cancer, cardiovascular disease, and late
neurodegeneration consistent with Human System Risk Board quality of life consequences.
2. Countermeasure efficacy based on human epidemiology and radiobiology data from NSRL.
Category:
Standard
Subcategory:
Deliverable Title:
Description:
Title: MERA 2024: Cancer RIsk Model
Transition to operational use of new approach to REID assessment using ensemble modeling. MERA 2024 provides an improved method for calculating REID and safe days in space for EM9 crews based on consensus approach. Information on cancer mortality projected into the future developed under the MERA project by the Potomac Institute will help inform how medical advances in the future may alter the actual risks during future missions. MERA 2024: Cancer Risk Model will have the ability to evaluate the Draft Cancer PEL. Evaluation of MCM's and EM9 crew selection. Model has been through external review.
Internal Customers:
None
External Customers:
2023
Human System Risk Board (HSRB)
Office of the Chief Health and Medical Officer (OCHMO)
Is a Customer-Supplier Agreement (CSA) Required?
No
Maturation Deliverable:
Standard
Primary Crew Health & Performance System Impact:
Medical
Secondary Crew Health & Performance System Impacts:
None
Mission:
Lunar Surface
Technology & Countermeasure Readiness Level (TRL/CRL):
Category:
Technology or Tool
Subcategory:
Computational Models or Simulations
Deliverable Title:
Description:
Title: MERA 2029: Multimodel Ensemble Risk Assessment
Updates to MERA include addition of combined cancer plus cardiovascular REID model, and inclusion of clinically based risk assessment models allowing family history/individualized risk factors to be considered. This information will support optimization of countermeasure strategies for individual crew. Update of cancer PEL to OCHMO as required -safe days in space calculations based on multi-model ensemble risk assessment (MERA) approach includes clinical risk assessment capability and combined CVD+Cancer REID assessment.
Internal Customers:
None
External Customers:
HMTA 2024
Is a Customer-Supplier Agreement (CSA) Required?
No
Maturation Deliverable:
Technology or Tool
Primary Crew Health & Performance System Impact:
Medical
Secondary Crew Health & Performance System Impacts:
None
Mission:
Mars Shakedown
Technology & Countermeasure Readiness Level (TRL/CRL):
Category:
Technology or Tool
Subcategory:
Computational Models or Simulations
Deliverable Title:
Description:
Title: MERA 2024:Clinical CVD Risk Model
There is a need to better understand an individual's risk for CVD due to space radiation exposure for clinical care and planning purposes. Will provide better information for individual medical decisions
Internal Customers:
None
External Customers:
HMTA 2024
Is a Customer-Supplier Agreement (CSA) Required?
No
Maturation Deliverable:
Technology or Tool
Primary Crew Health & Performance System Impact:
Medical
Secondary Crew Health & Performance System Impacts:
None
Mission:
Lunar Surface
Technology & Countermeasure Readiness Level (TRL/CRL):
Category:
Technology or Tool
Subcategory:
Computational Models or Simulations
Deliverable Title:
Description:
Title: V2020 MERA Anchor Model
Defines new NASA cancer risk model implementing documented Quality Factor (QF) functions, Dose and Dose-Rate Effectiveness Factor (DDREF) modules and low-LET epidemiology models. Will form baseline NASA input to the Multi-model Ensemble Risk Assessment (MERA). Responds to recommendations from NAS review.
Internal Customers:
None
External Customers:
HMTA
Is a Customer-Supplier Agreement (CSA) Required?
No
Maturation Deliverable:
Technology or Tool
Primary Crew Health & Performance System Impact:
Medical
Secondary Crew Health & Performance System Impacts:
None
Mission:
Gateway
Technology & Countermeasure Readiness Level (TRL/CRL):
Category:
Technology or Tool
Subcategory:
Computational Models or Simulations
Deliverable Title:
Description:
TItle: MERA 2030: Risk Landscape
The cross risk MERA 2030 model will compile and integrate all the risk modules into a complete capability to evaluate PELs and provide information for clinical care and planning regarding integrated Cancer and CVD risk along with CNS detriments
Internal Customers:
None
External Customers:
HMTA
Is a Customer-Supplier Agreement (CSA) Required?
No
Maturation Deliverable:
Technology or Tool
Primary Crew Health & Performance System Impact:
Medical
Secondary Crew Health & Performance System Impacts:
None
Mission:
Lunar Surface
Technology & Countermeasure Readiness Level (TRL/CRL):